A Phase 2, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel.
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2015
At a glance
- Drugs Ombrabulin (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms OPSALIN
- Sponsors Sanofi
- 07 Jun 2017 Biomarkers information updated
- 18 Jun 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 13 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History